Navigation Links
Heparin Use Prior to Endoscopic Vein Harvest Improves Graft Patency in Off-Pump Coronary Artery Bypass Patients
Date:6/8/2009

Pre-heparinization Limits Clot Retention and Decreases Residual Clot Volume

SAN FRANCISCO, June 8 /PRNewswire/ -- MAQUET Cardiovascular LLC announced today that data presented at the annual meeting of the International Society for Minimally Invasive Cardiothoracic Surgery show that administration of a heparin bolus with doses as low as 2500U prior to endoscopic vein harvest (EVH) was associated with improved acute saphenous vein (SV) graft patency in patients undergoing off-pump coronary artery bypass (OPCAB). Pre-heparinization was also linked to a significant reduction in the incidence and volume of residual clot strands within the vein.

In EVH, a small incision is made in the leg, through which an endoscope is passed and the vein harvested for coronary artery bypass graft (CABG) procedures. This method reduces patient discomfort and scarring.

EVH also significantly reduces wound complications and hastens recovery time compared to traditional techniques that involve a long incision to expose the entire length of the vein.

"In our experience, the impact of pre-heparinization on surgical bleeding is minimal, making it a promising strategy that may improve patient outcomes with minimally invasive vein harvesting," said lead investigator Robert Poston, M.D., Chief, Division of Cardiac Surgery, Boston University.

The prospective study examined acute patency rates in 460 patients that underwent OPCAB using veins acquired through EVH, comparing patients receiving no heparin prior to harvest (n=306) to those who received one of three doses of heparin prior to the procedure (n=181). A subset of the most recent 110 patients underwent catheter-based infrared imaging (OCT) of the full tract of harvested SV in order to measure residual clot within the vein. Overall, vein graft patency was 98.9 percent in patients treated with heparin compared to 95.2 percent in
'/>"/>

SOURCE MAQUET Cardiovascular LLC
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Interface Biologics Anti-Thrombic Additives Show Equivalent Efficacy to Commercial Heparinized Coatings
2. ISAR-REACT 3 Pits Bivalirudin vs. Unfractionated Heparin in PCI
3. Study Shows That Low-Molecular Weight Heparin (LMWH) was Associated with Reduced Hospital Costs of Venous Thromboembolism (VTE) Treatment Compared with Unfractionated Heparin (UFH)
4. Pixantrone Produces High Rates of Complete and Partial Remissions Even Among Aggressive NHL Patients With Extensive Prior Doxorubicin Treatment or Prior Rituximab Treatment
5. Alimera Sciences Iluvien(TM) Phase 3 Studies for DME Pass Final DSMB Review Prior to October Readout
6. Blood Testing Identifies Abnormal Cells Up to Six Years Prior to Leukemia Diagnosis
7. FDA Grants Priority Review of a Supplemental Biologics License Application for Cinryze(TM) C1 Inhibitor (Human) as Treatment for Acute Attacks of Hereditary Angioedema (HAE)
8. RAD001 Phase II Trial Results Positive in Patients with Advanced Gastric Cancer After Failure of One or More Prior Treatments
9. ACTEMRA (R) (tocilizumab) Significantly Reduced Signs and Symptoms of Rheumatoid Arthritis in Patients Who Failed Prior Treatments
10. RAD001 Granted Priority Review in the US Based on Potential to Fill Unmet Medical Need in Patients With Advanced Kidney Cancer
11. REMOXY(R) NDA Filing Accepted by FDA and Priority Review Granted
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... BURLINGTON, Mass. , June 18, 2013 Decision ... for pharmaceutical and healthcare issues, finds that, over the past ... ( France , Germany , ... and the United Kingdom ) have been ... most of their HIV patients, primarily to reduce costs. Additionally, ...
(Date:6/18/2013)... NEW YORK , June 18, 2013 JDRF ... ) are accelerating the development of new products that combine ... new collaboration announced today. This new, three-year commitment is an ... (T1D). Many patients with T1D not only take ... to be placed in the body for a number of ...
(Date:6/18/2013)... 2013 Today, Wall Street Reports announced ... GILD ), Health Management Associates Inc. (NYSE: HMA ... Pharmaceuticals Inc. (NASDAQ: ISIS ), and Trius Therapeutics ... of charge - including full price targets, industry analysis and ... Sciences, Inc. Research Report On June 7, 2013, ...
Breaking Medicine Technology:One in Four Surveyed EU5 Physicians Has Been Required to Change a Prescription for Some or Most of Their HIV Patients in the Past Twelve Months, Primarily to Reduce Costs 2One in Four Surveyed EU5 Physicians Has Been Required to Change a Prescription for Some or Most of Their HIV Patients in the Past Twelve Months, Primarily to Reduce Costs 3JDRF Extends Collaboration with BD to Develop Combined Infusion and Monitoring Products for People with Type 1 Diabetes 2JDRF Extends Collaboration with BD to Develop Combined Infusion and Monitoring Products for People with Type 1 Diabetes 3Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 2Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 3Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 4Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 5Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 6
... announces that a new market research report is ... Urological Catheters Industry http://www.reportlinker.com/p087354/Global-Urological-Catheters-Industry.html ... worldwide markets for Urological Catheters in Thousand Units ... Dialysis Catheters (Hemodialysis, & Peritoneal), and Urinary Catheters ...
... Inc., a full service contract biomanufacturing company, today ... Development and Manufacturing Agreement with a multinational biopharmaceutical ... the process to manufacture a unique therapeutic monoclonal ... will be manufactured under cGMP conditions as a ...
Cached Medicine Technology:Reportlinker Adds Global Urological Catheters Industry 2Reportlinker Adds Global Urological Catheters Industry 3Reportlinker Adds Global Urological Catheters Industry 4Reportlinker Adds Global Urological Catheters Industry 5Reportlinker Adds Global Urological Catheters Industry 6Reportlinker Adds Global Urological Catheters Industry 7Reportlinker Adds Global Urological Catheters Industry 8Reportlinker Adds Global Urological Catheters Industry 9Reportlinker Adds Global Urological Catheters Industry 10Reportlinker Adds Global Urological Catheters Industry 11Reportlinker Adds Global Urological Catheters Industry 12Reportlinker Adds Global Urological Catheters Industry 13Reportlinker Adds Global Urological Catheters Industry 14Reportlinker Adds Global Urological Catheters Industry 15Reportlinker Adds Global Urological Catheters Industry 16Reportlinker Adds Global Urological Catheters Industry 17Reportlinker Adds Global Urological Catheters Industry 18Reportlinker Adds Global Urological Catheters Industry 19Reportlinker Adds Global Urological Catheters Industry 20Reportlinker Adds Global Urological Catheters Industry 21Reportlinker Adds Global Urological Catheters Industry 22Reportlinker Adds Global Urological Catheters Industry 23Reportlinker Adds Global Urological Catheters Industry 24Reportlinker Adds Global Urological Catheters Industry 25Reportlinker Adds Global Urological Catheters Industry 26Goodwin Biotechnology Announces Signing New Biopharmaceutical Development & Manufacturing Agreement 2
(Date:6/18/2013)... Palo Alto has taken yet another step ... with its recent major long-term solar power commitment. , ... electric power purchase agreements , which together will result in ... photovoltaic electric power per year, which is the equivalent of ... enough power to supply all 65,000+ Palo Alto residents---and then ...
(Date:6/18/2013)... 2013 Seven-year-old Riley Salz of Encino, ... He receives 40 hours a week of applied behavior ... the Center for Autism and Related Disorders (CARD). Riley ... and has experienced remarkable progress, including learning to speak, ... Riley’s personal journey through autism is now featured in ...
(Date:6/18/2013)... Hospitals Case Medical Center clinical researchers have launched ... which will evaluate the ability of a patient,s ... end stage peripheral arterial disease (PAD). , ... Surgery at University Hospitals Case Medical Center,s Harrington ... at Case Western Reserve University School of Medicine, ...
(Date:6/18/2013)... 18, 2013 More than 1.1 million people ... HIV/AIDS, according to the Centers for Disease Control and Prevention ... infected. In support of National HIV Testing Day on June ... Insurance (SSDI) representation, the CDC and other organizations are ... The CDC reports about 50,000 new HIV infections each year. ...
(Date:6/18/2013)... myCNAjobs announces the addition of new resources to ... to the Caregiver Resources Center. , As more caregivers ... baby boomers each day, the need for caregiver ... has never been greater. myCNAjobs, the fastest growing ... the first-ever free resource center for caregivers seeking professional ...
Breaking Medicine News(10 mins):Health News:Palo Alto Seals the Deal on Major Solar Electric Investments 2Health News:Palo Alto Seals the Deal on Major Solar Electric Investments 3Health News:June's Release of CARD's "Mission Possible: Portraits of Hope" Features Southern California Child and His Remarkable Progress with Intensive Autism Therapy 2Health News:June's Release of CARD's "Mission Possible: Portraits of Hope" Features Southern California Child and His Remarkable Progress with Intensive Autism Therapy 3Health News:UH Case Medical Center launches novel clinical trial using stem cells to prevent amputation 2Health News:Allsup Observes National HIV Testing Day June 27 2Health News:Allsup Observes National HIV Testing Day June 27 3Health News:myCNAjobs Adds New Resources to Growing Caregiver Career Center 2
... FAIRFAX, Va., Sept. 25 The American Society,for ... version of,its brochure Radiation Therapy for Gynecologic Cancers. ... useful information on the,different types of radiation therapy ... on the potential side effects and how to ...
... Australia have shown that positron emission tomography (PET) ... useful than mammography and ultrasound in predicting a ... patients ultimate likelihood of survival. , In research ... (ECCO 14) in Barcelona, Dr Vinod Ganju reported ...
... new song has helped scientists open a new avenue of ... there is currently no cure or even a treatment to ... in the Journal of Clinical Investigation, scientists at the University ... someday be used to treat the disease. The team used ...
... found that the breast cancer susceptibility gene, BRCA1, plays a ... can it be used to predict outcome for patients with ... tool in choosing the best therapy for them. , Dr ... 14) in Barcelona, that analysis of the expression of five ...
... gliomas (BSGs) are rare but can be very difficult ... survival rates. However, a team of Spanish researchers have ... (I/C) produced rapid clinical responses and shrank the tumours ... enrolled in a clinical trial. , Dr Jaume Mora ...
... Researchers in The Netherlands have developed a method of ... likely to have their disease recur after surgery and ... chemotherapy. , Led by Professor Rob Tollenaar at Leiden ... at The Netherlands Cancer Institute, they have analysed for ...
Cached Medicine News:Health News:Updated Brochure on Gynecologic Cancer Treatments Now Available 2Health News:PET scans can accurately detect a breast tumor's response to chemotherapy 2Health News:PET scans can accurately detect a breast tumor's response to chemotherapy 3Health News:Stem cells show promise for treating Huntington's disease 2Health News:Stem cells show promise for treating Huntington's disease 3Health News:Stem cells show promise for treating Huntington's disease 4Health News:Breast cancer susceptibility gene predicts outcome and response to treatment in lung cancer 2Health News:Breast cancer susceptibility gene predicts outcome and response to treatment in lung cancer 3Health News:New chemotherapy regimen prolongs survival in difficult-to-treat childhood brainstem gliomas 2Health News:Molecular profiling can accurately predict survival in colon cancer patients 2Health News:Molecular profiling can accurately predict survival in colon cancer patients 3
... The Clariflex® Intraocular Lens is indicated ... years of age or older in whom ... IOL is a third-generation IOL design made ... is designed both to reduce internal reflections ...
... Lenses: The Bausch & Lomb PMMA Posterior Chamber ... primary implantation for the visual correction of aphakia ... where a cataractous lens has been removed by ... be placed in the ciliary sulcus or capsular ...
... USIOL lenses are manufactured using ... processes. Perspex CQ UV PMMA ... multi-piece and single piece lenses. ... in both nonphaco and phaco ...
... II is a sterile nonpyrogenic, transparent viscoelastic ... II contains 12 mg/ml of high molecular ... hyaluronate dissolved in physiological saline. In the ... is 105,000 cps (105 Pa s) at ...
Medicine Products: